Nusinersen/Spinraza EAP program closes in November for newly diagnosed SMA Type 1 babies

What a sad news for England. After Sprinraza was not approved in England and Wales, dies the last hope for parents.

Biogen informed TreatSMA.
Nusinersen Expanded Access Programme will close for new patients on 1 November 2018, infants that currently participating in the program will continue without changes

Publisert av


Until those day, was my kiss of death been stronger than those of the devil. I like to ride through hellfire with him ,when I come out victorious afterwards. I'm strong and proud rheumatoid arthritis warrior Följ mig, tack! Liz - Fotoblogg Spelblogg